Management of the elderly patients with inflammatory bowel disease: Practical considerations

Inflammatory Bowel Diseases

Volumn 19, Issue 10, 2013, Pages 2257-2272

  Katz, Seymour ^a,b,c   Surawicz, Christina ^d   Pardi, Darrell S ^e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c ST FRANCIS HOSPITAL   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIBIOTIC AGENT; AZATHIOPRINE; CIMETIDINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DILTIAZEM; ENEMA; EPHEDRINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NICARDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLSALAZINE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; SALAZOSULFAPYRIDINE; TIOGUANINE; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ABSCESS; AGED; AGING; ALLERGIC REACTION; ANTICOAGULANT THERAPY; ARTHRALGIA; ASTHMA; BIOLOGICAL THERAPY; BLOODY DIARRHEA; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CANCER RISK; CANCER SCREENING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC LUNG DISEASE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; COLON ULCER; COLORECTAL CANCER; COMORBIDITY; CONGESTIVE HEART FAILURE; CROHN DISEASE; CYTOPENIA; DEMENTIA; DIABETES MELLITUS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG COST; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; ENTERITIS; FEVER; FINANCIAL MANAGEMENT; FITNESS; FRACTURE; FRAGILITY FRACTURE; FRAIL ELDERLY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SURGERY; GERIATRIC PATIENT; GROUPS BY AGE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERICUM PERFORATUM; HYPERTENSION; ILEITIS; ILEOANAL ANASTOMOSIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; INTERSTITIAL NEPHRITIS; INTESTINE PERFORATION; INTESTINE ULCER; ISCHEMIC COLITIS; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; LOW DRUG DOSE; MEDICAL HISTORY; MENTAL INSTABILITY; MICROSCOPIC COLITIS; NEPHROTOXICITY; PANCOLITIS; PANCREATITIS; PATIENT COMPLIANCE; PEPTIC ULCER; PERIPHERAL VASCULAR DISEASE; POLYPHARMACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCTITIS; PROCTOCOLECTOMY; RADIATION INJURY; RASH; REVIEW; RHEUMATIC DISEASE; SOCIAL ASPECT; SUPPOSITORY; TOXIC MEGACOLON; ULCERATIVE COLITIS; ULCERATIVE PROCTITIS; ULCERATIVE PROCTOSIGMOIDITIS; UNITED STATES; VACCINATION;

AGED; AGING; COMORBIDITY; DISEASE MANAGEMENT; HUMANS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS;

EID: 84884550493     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31828c8536     Document Type: Review

References (226)

1. Americans Committee on the Future Health Care Workforce for Older Americans, Institute of Medicine. Retooling for an Aging America: Building the Health Care Workforce. The National Academies Press; 2008.
2. Hussain SW, Pardi DS. Inflammatory bowel disease in the elderly. Drugs Aging. 2010;27:617-624.
3. Grimm IS, Friedman LS. Inflammatory bowel disease in the elderly. Gastroenterol Clin North Am. 1990;19:361-389.
4. Piront P, Louis E, Latour P, et al. Epidemiology of inflammatory bowel diseases in the elderly in the province of Leíge. Gastroenterol Clin Biol. 2002;26:157-161.
5. Jones HW, Hoare AM. Does ulcerative colitis behave differently in the elderly? Age Ageing. 1988;17:410-414.
6. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted county Minnesota 1940-1993: incidence, prevalence, and survival. Gastroenterology. 1998;114:1161-1168.
7. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative Colitis in Olmsted county Minnesota 1940-1993: incidence, prevalence, and survival. Gut. 2000;46:336-343.
8. Loftus CG, Loftus EV, Harmsen S, et al. Update on the incidence and prevalence of Crohn's disease and Ulcerative Colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007;13:254-261.
9. Bernstein CN, Blanchard JF, Rawsthorne P, et al. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol. 1999;149:916-924.
10. Molinié F, Gower-Rousseau C, Yzet T, et al. Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999). Gut. 2004;53:843-848.
11. Ott C, Obermeier F, Thieler S, et al. The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population based study. Eur J Gastroenterol Hepatol. 2008;20:917-923.
12. Lapidus A, Bernell O, Hellers G, et al. Incidence of Crohn's disease in Stockholm County 1955-1989. Gut. 1997;41:480-486.
13. Nerich V, Monnet E, Etienne A, et al. Geographical variations of inflammatory bowel disease in France: a study based on national health insurance data. Inflamm Bowel Dis. 2006;12:218-226.
14. Evans JG, Acheson ED. An epidemiological study of ulcerative colitis and regional enteritis in the Oxford area. Gut. 1965;6:311-324.
15. Burch PR, de Dombal FT, Watkinson G. Aetiology of ulcerative colitis. II. A new hypothesis. Gut. 1969;10:277-284.
16. Lee F, Costello FT. Crohn's disease in Blackpool-incidence and prevalence 1968-80. Gut. 1985;26:274-278.
17. Terell KB, Garland FC. Incidence rates of ulcerative colitis and Crohn's disease in fifteen areas of the United States. Gastroenterology. 1981;81: 1115-1124.
18. Garland CF, Lilienfeld AM, Mendeloff al, et al. Incidence rates of ulcerative colitis and Crohn's disease in fifteen areas of the United States. Gastroenterology. 1981;81:1115-1124.
19. Rose JD, Roberts GM, William RG. Cardiff Crohn's disease jubilee: the incidence over 50 years. Gut. 1988;29:346-351.
20. Herrinton LJ, Liu L, Lewis JD, et al. Incidence and prevalence of inflammatory bowel disease in a northern California managed care organization, 1996-2002. Am J Gastroenterol. 2008;103:1998-2006.
21. Shah S, Leleiko N, Lidofsky S, et al. Ocean State Crohn's and Colitis Area Registry (OSCCAR): incidence of Crohn's disease and ulcerative colitis in a prospective, population-based inception cohort in Rhode Island. Am J Gastroenterol. 2010;92:Abstract 1172.
22. Russel M, Stockbrügger R. Epidemiology of inflammatory bowel disease: an update. Scand J Gastroenterol. 1996;31:417-427.
23. Evans PE, Pardi DS. Inflammatory bowel disease in the elderly. Aging Health. 2007;3:77-84.
24. Greenwald DA, Brandt LJ. Inflammatory bowel disease after age 60. Curr Treat Options Gastroenterol. 2003;6:213-225.
25. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39:690-697.
26. Frangos CC, Frangos CC. Inflammatory bowel disease: reviewing and old study under a new perspective. Gut. 2007;56:1638-1639.
27. Quezada S, Cross R. Impact of age at diagnosis and Crohn's disease phenotype. Am J Gastroenterol. 2010;105:Abstract 1199.
28. Zimmerman J, Gavish D, Rachmilewitz D. Early and late onset ulcerative colitis: distinct clinical features. J Clin Gastroenterol. 1985;7:492-498.
29. Softley A, Myren J, Clamp SE, et al. Inflammatory bowel disease in the elderly patient. Scand J Gastroenterol Suppl. 1988;144:27-30.
30. Wagtmans MJ, Verspaget HW, Lamers CB, et al. Crohn's disease in the elderly: a comparison with young adults. J Clin Gastroenterol. 1998;27: 129-133.
31. Harper PC, McAuliffe TL, Beeken WL. Crohn's disease in the elderly. A statistical comparison with younger patients matched for sex and duration of disease. Arch Intern Med. 1986;146:753-755.
32. Greth J, Török HP, Koenig A, et al. Comparison of inflammatory bowel disease at younger and older age. Eur J Med Res. 2004;9:552-554.
33. Polito JM II, Childs B, Mellits ED, et al. Crohns disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology. 1996; 111:580-586.
34. Charpentier C, Gower-Rousseau C, Savoye G, et al. Natural history of Crohn's disease in the elderly: a population-based study. Poster presented at: Digestive Disease Week; May 19-22, 2012. San Diego, CA. Abstract 106.
35. Charpentier C, Salleron J, Savoye G, et al. Natural History of Ulcerative Colitis in the Elderly: a Population-Based Study. Poster presented at: Digestive Disease Week; May 19-22, 2012; San Diego, CA. Abstract 105.
36. Lakatos PL, David G, Pandur T, et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. J Crohn's Colitis. 2011;5:5-13.
37. Juneja M, Baidoo L, Schwartz MB, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comborbidity. Dig Dis Sci. 2012;57:2408-2415.
38. Udell JA, Steg PG, Scirica BM, et al. Living alone and cardiovascular risk in outpatients at risk of or with atherothrombosis. Arch Intern Med. 2012;172:1086-1095.
39. Picco MF, Cangemi JR. Inflammatory bowel disease in the elderly. Gastroenterol Clin North Am. 2009;38:447-462.
40. Surawicz CM, Haggitt RC, Hussemann M, et al. Mucosal biopsy diagnosis of colitis: acute self-limited and acute idiopathic inflammatory bowel disease. Gastroenterology. 1994;107:755-763.
41. Harpaz N, Sachar DB. Segmental colitis associated with diverticular disease and other IBD look-alikes. J Clin Gastroenterol. 2006;4(suppl 30):S132-S135.
42. Nielsen OH, Vainer B, Rask-Madden J. Non-IBD and noninfectious colitis. Nat Clin Pract Gastroenterol Hepatol. 2008;5:28-39.
43. Freeman HJ. Natural History and long-term clinical behavior of segmental colitis associated with diverticulosis (SCAD Syndrome). Dig Dis Sci. 2008;53:2452-2457.
44. Peppercorn MA. Drug-responsive chronic segmental colitis associated with diverticula: a clinical syndrome in the elderly. Am J Gastroenterol. 1992;87:609-612.
45. Das R, Feuerstadt P, Brandt LJ. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with clostridium difficile-associated disease. Am J Gastroenterol. 2010;105:2040-2049.
46. Ananthakrishnan AN, Guzman-Perez R, Gainer V, et al. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:789-795.
47. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31:431-455.
48. Shen B, Jiang Z, Fazio VW, et al. Clostridium difficile in patients with ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2008;6:782-788.
49. Hawkey CJ. NSAIDs, coxibs, and the intestine. J Cardiovasc Pharmacol. 2006;47(suppl 1):S72-S75.
50. Faucheron JL. Toxicity of non-steroidal anti-inflammatory drugs in the large bowel. Eur J Gastroenterol Hepatol. 1999;11:389-392.
51. Takeuchi K, Smale S, Puroshothaman P, et al. Prevalence and mechanism of non-steroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:196-202.
52. Juneja M, El Mourabet M, Swoger J, et al. NSAIDs and hormone replacement therapy in geriatric Crohn's Disease. Am J Gastroenterol. 2010;Abstract 294.
53. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo controlled pilot study. Clin Gastroenterol Hepatol. 2006;4:203-211.
54. Juneja M, Mourabet ME, Baidoo L, et al. Aspirin use in geriatric Crohn's disease. Am J Gastroenterol. 2010;105:Abstract 1260.
55. Korotinski S, Katz A, Malnick DH. Chronic ischaemic bowel diseases in the aged-go with the flow. Age Ageing. 2005;34:10-16.
56. Green BT, Tendler DA. Ischemic colitis: a clinical review. South Med J. 2005;98:217-222.
57. Boehmer ED, Goral J, Faunce DE, et al. Age-dependent decrease in Toll-like receptor 4-mediated proinflammatory cytokine production and mitogenactivated protein kinase expression. J Leukoc Biol. 2004;75:342-349.
58. van Duin D, Mohanty S, Thomas V, et al. Age-associated defect in human TLR-1/2 function. J Immunol. 2007;178:970-975.
59. Ogawa T, Kitagawa M, Hirokawa K. Age-related changes of human bone marrow: a histometric estimation of proliferative cells, apoptotic cells, T cells, B cells and macrophages. Mech Ageing Dev. 2000;117:57-68.
60. Plowden J, Renshaw-Hoelscher M, Engleman C, et al. Innate immunity in aging: impact on macrophage function. Aging Cell. 2004;3:161-167.
61. Agius E, Lacy KE, Vukmanovic-Stejic M, et al. Decreased TNF-alpha synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging. J Exp Med. 2009;206:1929-1940.
62. Borrego F, Alonso MC, Galiani MD, et al. NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol. 1999;34: 253-265.
63. Hayhoe RP, Henson SM, Akbar AN, et al. Variation of human natural killer cell phenotypes with age: indentification of a unique KLRG1- negative subset. Hum Immunol. 2010;71:676-681.
64. Jing Y, Shaheen E, Drake RR, et al. Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood. Hum Immunol. 2009;70:777-784.
65. Panda A, Qian F, Mohanty S, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol. 2010;184:2518-2527.
66. Flores KG, Li J, Sempowski GD, et al. Analysis of the human thymic perivascular space during aging. J Clin Invest. 1999;104:1031-1039.
67. Kaltoft K. Cytokine-driven immortalization of in vitro activated human T lymphocytes. CD 28 expression correlates inversely with cell population doublings. Exp Clin Immunogenet. 1998;15:84-89.
68. Xiao ZQ, Moragoda L, Jaszewski R, et al. Aging is associated with increased proliferation and decreased apoptosis in the colonic mucosa. Mech Ageing Dev. 2001;122:1849-1864.
69. Frasca D, Blomberg BB. Effects of aging on B cell function. Curr Opin Immunol. 2009;21:425-430.
70. Frasca D, Landin AM, Lechner SC, et al. Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in B cells. J Immunol. 2008;180:5283-5290.
71. Lazuardi L, Jenewein B, Wolf AM, et al. Age-related loss of naïve T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology. 2005;114:37-43.
72. Gibson KL, Wu YC, Barnett Y, et al. B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell. 2009;8:18-25.
73. Drey M, Kaiser MJ. Malnutrition in the elderly [Article in German]. Dtsch Med Wochenschr. 2011;136:176-178.
74. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis. 2002;2: 659-666.
75. Chandra RK. Nutrition and the immune system from birth to old age. Eur J Clin Nutr. 2002;56(suppl 3):S73-S76.
76. Bhushan A, Pardi DS, Loftus EV, et al. Age is not associated with adverse events from biologic therapy in patients with inflammatory bowel disease. Poster presented at: Digestive Disease Week; May 1-5, 2010; New Orleans, LA. 2010;138: Abstract 413. (Revised).
77. Brandt L, Boley S, Goldberg L, et al. Colitis in the elderly. A reappraisal. Am J Gastroenterol. 1981;76:239-245.
78. Shapiro PA, Peppercorn MA, Antoniolo DA, et al. Crohn's disease in the elderly. Am J Gastroenterol. 1981;76:132-137.
79. Lichtenstein GR, Sands BE, Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12:797-813.
80. Pardi DS, Loftus EV Jr, Camilleri M. Treatment of inflammatory bowel disease in the elderly: an update. Drugs Aging. 2002;19:355-363.
81. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomized, double blind, placebo controlled study. Gut. 2005;54:960-965.
82. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92: 1867-1871.
83. Rao SS; American College of Gastroenterology Practice Parameters Committee. Diagnosis and management of fecal incontinence. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol. 2004;99:1585-1604.
84. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-523.
85. Kane S, Katz S, Jamal MM, et al. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. Inflamm Bowel Dis. 2012;18:1026-1033.
86. Kane SV, Summer M, Solomon D, et al. Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. Dig Dis Sci. 2011;56: 3463-3470.
87. Hanauer SB, Strömberg U. Oral pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004;2:379-388.
88. Muller AF, Stevens PE, McIntyre AS, et al. Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther. 2005;21: 1217-1224.
89. Gisbert JP, González-Lama Y, Maté J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007;13:629-638.
90. Gisbert JP, Luna M, González-Lama Y, et al. Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study. Gastroenterol Hepatol. 2008;31:477-484.
91. Mogul Z, Feldstein R, Katz S. Long-term Safety of 5-ASA (mesalamine) in the treatment of inflammatory bowel disease in the elderly. Am J Gastroenterol. 2009;104:S432. Abstract 1171.
92. Lichtenstein GR, Merchant K, Shaw AL, et al. Efficacy of mesalamine granules for maintenance of remission in patients recently treated with corticosteroids. Poster presented at: Digestive Disease Week; May 30- June 4, 2009; Chicago, IL. Abstract T1204.
93. Wells PS, Hollbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food. Ann Intern Med. 1994;121:676-683.
94. de Boer NK, Wong DR, Jharap B, et al. Dose-dependent influence of 5- aminosalicylates on thiopurine metabolism. Am J Gastroenterol. 2007; 102:2747-2753.
95. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61:246-255.
96. McAllister WA, Thompson PJ, Al-Habet SM, et al. Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed). 1983;286:923-925.
97. Finch CK, Chrisman CR, Baciewicz AM, et al. Rifampin and rifabutin drug interactions: an update. Arch Intern Med. 2002;162:985-992.
98. Bell EC, Ravis WR, Chan HM, et al. Lack of pharmacokinetics interaction between St John's Wort and Prednisone. Ann Pharmacother. 2007; 41:1819-1824.
99. Thomas TP. The complications of systemic corticosteroid therapy in the elderly. A retrospective study. Gerontology. 1984;30:60-65.
100. Akerkar GA, Peppercorn MA, Hamel MB, et al. Corticosteroid-associated complications in elderly Crohn's disease patients. Am J Gastroenterol. 1997;92:461-464.
101. Tilg H, Moschen AR, Kaser A, et al. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut. 2008;57:684-694.
102. Sandborn WJ, Tremaine WJ, Wolf DC. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology. 1999;117:527-535.
103. Lennard L. Clinical implications of thiopurine methyltransferase- optimization of drug dosage and potential drug interactions. Ther Drug Monit. 1998;20:527-531.
104. Bergan S, Rugstad HE, Bentdal O, et al. Monitoring of azathioprine treatment by determination 6-thioguanine nucleotide concentrations in erythrocytes. Transplantation. 1994;58:803-808.
105. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132-142.
106. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogentics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651-662.
107. Weinshilboum R. Methyltransferase pharmacogenetics. Pharmacol Ther. 1989;43:77-90.
108. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641-649.
109. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34:1081-1085.
110. Bouhnik Y, Lémann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996;347:215-219.
111. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ Registry. Am J Gastroenterol. 2012;107: 1409-1422.
112. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051-1063.
113. Ansari A, Patel N, Sanderson J. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:640-647.
114. Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007;5:209-214.
115. Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005;22:441-446.
116. Govani SM, Higgins PD. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J Crohns Colitis. 2010;4: 444-449.
117. Afzali A, Wheat C, Lee S. Assessment of the efficacy of oral methotrexate in conjunction with infliximab therapy for the treatment of inflammatory bowel disease. Poster presented at: Digestive Disease Week; May 19-22, 2012. San Diego, CA. Abstract Tu1309.
118. Landewé RB, van den Borne BE, Breedveld FC, et al. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet. 2000;355:1616-1617.
119. Methotrexate: drug information. Lexi-Comp, Inc., OH. 2007.
120. Irving PM, Shanahan F, Rampton DS. Drug interactions in inflammatory bowel disease. Am J Gastroenterol. 2008;103:207-219.
121. Wilson A, Patel V, Kim R, et al. Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease. Poster presented at: Digestive Disease Week; May 19-22, 2012. San Diego, CA. Abstract 1552.
122. Khan N, Abbas A, Moehlen M, et al. Methotrexate in ulcerative colitis: a nationwide retrospective cohort from the Veterans Affairs Healthcare System. Poster presented at: Digestive Disease Week; May 19-22, 2012. San Diego, CA. Abstract 1704.
123. Kornbluth A, Present DH, Lichtiger S, et al. Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol. 1997;92:1424-1428.
124. Fernández-Bañares F, Bertrán X, Esteve-Comas M. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol. 1996;91: 2498-2499.
125. Cyclosporine: drug information. Lexi-Comp, Inc., OH 2006.
126. Sketris IS, Methot ME, Nicol D, et al. Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. Ann Pharmacother. 1994;28:1227-1231.
127. Iven H, Brasch H. Influence of the antibiotics piperacillin, doxycycline, and tobramycin on the pharmacokinetics of methotrexate in rabbits. Cancer Chemother Pharmacol. 1986;17:218-222.
128. Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neural)1 in organ transplantation. Drugs. 2001;61:1957-2016.
129. Mantzaris GJ, Hatzis A, Kontogiannis P, et al. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol. 1994;89:43-46.
130. Mantzaris GJ, Archavlis E, Christoforidis P, et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol. 1997;92:454-456.
131. Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs. 1997;54:679-708.
132. Ciprofloxacin: drug information. Lexi-Comp, Inc., OH. 2007.
133. Shakeri-Nejad K, Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother. 2006;7:639-651.
134. Marchbanks CR. Drug-drug interactions with fluoroquinolones. Pharmacotherapy. 1993;13(2 pt 2):23S-28S.
135. Mott FE, Murphy S, Hunt V. Ciprofloxacin and warfarin. Ann Intern Med. 1989;111:542-543.
136. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20:757-790.
137. Fülöp T, Larbi A, Hirokawa K, et al. Immunosupportive therapies in aging. Clin Interv Aging. 2007;2:33-54.
138. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936.
139. Cottone M, Kohn A, Daperno M, et al. Anti-TNF therapy in elderly people in IBD: an Italian multicentre survey. Poster presented at: Digestive Disease Week; May 1-5, 2010; New Orleans, LA. Abstract W1271.
140. Desai A, Zator Z, De Silva PS, et al. The safety profile of anti-TNF therapy in an older population with inflammatory bowel disease. Poster presented at: Digestive Disease Week; May 19-22, 2012. San Diego, CA. Abstract Sa266.
141. Manten E, Green J, Bartholomew C. Primary care considerations in the management of inflammatory bowel disease patients. Pract Gastroenterol. 2012;4:48-54.
142. Rustagi T, Rai M, Diez L. Is inflammatory bowel disease a risk factor for coronary artery disease? Am J Gastroenterol. 2010;105:Abstract 1261.
143. Almogy G, Sachar DB, Bodian CA, et al. Surgery for ulcerative colitis in elderly persons: changes in indications for surgery and outcome over time. Arch Surg. 2001;136:1396-1400.
144. Cohen JL, Strong SA, Hyman NH, et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum. 2005;48: 1997-2009.
145. Chapman JR, Larson DW, Wolff BG, et al. Ileal pouch-anal anastomosis: does age at the time of surgery affect outcome? Arch Surg. 2005;140: 534-539.
146. Vavricka SR, Rogler G. Treatment of severe ulcerative colitis: differences in elderly patients? 2009;27:315-321.
147. Andersson P, Söderholm JD. Surgery in ulcerative colitis: indication and timing. Dig Dis. 2009;27:335-340.
148. Aberra FN, Lewis JD, Hass D, et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003;125:320-327.
149. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204:956-962.
150. Mor IJ, Vogel JD, da Luz Moreira A, et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum. 2008;51: 1202-1207.
151. Shen B, Angermeier KW, Remzi FH, et al. Screening and diagnosis of prostate cancer in patients with ileal pouch-anal anastomosis: consensus from an expert panel. Am J Gastroenterol. 2011;106:186-189.
152. Triantafillidis JK, Emmanouilidis A, Pomonis E, et al. Ulcerative colitis in the elderly: clinical patterns and outcome in 51 Greek patients. J Gastroenterol. 2001;36:312-316.
153. Roberts PL, Schoetz DJ Jr, Pricolo R, et al. Clinical course of Crohn's disease in older patients. A retrospective study. Dis Colon Rectum. 1990; 33:458-462.
154. Ha C, Bayless T, Bitton A, et al. Late adult-onset inflammatory bowel disease patients require surgery earlier during their disease course compared to early adult-onset patients. Poster presented at: Digestive Disease Week; 2012. Abstract Sa1248.
155. Guy TS, Williams NN, Rosato EF. Crohn's disease of the colon. Surg Clin North Am. 2001;81:159-168.
156. Triantafillidis JK, Emmanouilidis A, Nicolakis D, et al. Crohn's disease in the elderly: clinical features and long-term outcome of 19 Greek patients. Dig Liver Dis. 2000;32:498-503.
157. Brandt LJ, Dickstein G. Inflammatory bowel disease: specific concerns in the elderly. Geriatrics. 1989;44:107-111.
158. Rutz HP. Effects of corticosteroid use on treatment of solid tumours. Lancet. 2002;360:1969-1970.
159. Sørensen HT, Mellemkjaer L, Nielsen GL, et al. Skin cancers and non-Hodgkin lymphoma among users of systemic glucocorticoids: a populationbased cohort study. J Natl Cancer Inst. 2004;96:709-711.
160. Jensen AØ, Thomsen HF, Engebjerg MC, et al. Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study. Br J Cancer. 2009;100:200-205.
161. Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002;99:3909-3915.
162. Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268-274.
163. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1621-1628.
164. Singh H, Nugent Z, Demers AA, et al. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology. 2011;141:1612-1620.
165. Conraads VM, Denollet J, Vorlat A, et al. Screening for solid organ malignancies prior to heart transplantation. Transplantation. 2001;71: 1481-1483.
166. Moloney FJ, Comber H, O'Lorcain P, et al. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol. 2006;154:498-504.
167. Harwood CA, Attard NR, O'Donovan P, et al. PTCH mutations in basal cell carcinomas from azathioprine-treated organ transplant recipients. Br J Cancer. 2008;99:1276-1284.
168. Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood. 2004;104:822-828.
169. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs. 2007;67:1167-1198.
170. Beaugerie L. Inflammatory bowel disease therapies and cancer risk: where are we and where are we going? Gut. 2017;61:476-483.
171. Quinn MJ, d'Onofrio A, Møller B, et al. Cancer mortality trends in the EU and acceding countries up to 2015. Ann Oncol. 2003;14:1148-1152.
172. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation. 1993;55:742-747.
173. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011;140:1807-1816.
174. Goel GA, Kandiel A, Achkar JP, et al. Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications. Am J Gastroenterol. 2011;106:719-730.
175. Leedham SJ, Graham TA, Oukrif D, et al. Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology. 2009;136:542-550.
176. Kahi CJ, Rex DK, Imperiale TF. Screening, surveillance, and primary prevention for colorectal cancer: a review of the recent literature. Gastroenterology. 2008;135:380-399.
177. Rubin PH, Friedman S, Harpaz N. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology. 1999;117:1295-1300.
178. Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology. 1999;117:1288-1294.
179. Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003;124:880-888.
180. Hurlstone DP, Sanders DS, Lobo AJ, et al. Indigo carmine-assisted highmagnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy. 2005;37:1186-1192.
181. Itzkowitz SH, Present DH; Crohn's and Colitis Foundation of America Colon Cancer in IBD Study Group. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314-321.
182. van Schaik FD, van Oijen MG, Smeets HM, et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut. 2012;61:235-240.
183. Beaugerie L, Seksik P, Bouvier AM, et al. Thiopurine therapy is associated with a three-fold decrease in the incidence of advanced colorectal neoplasia in IBD patients with longstanding extensive colitis: results from the CESAME Cohort. Gastroenterology. 2009;136:A-54.
184. Watermeyer G, Locketz M, Govender D, et al. Crohn's disease-associated small bowel adenocarcinoma with pre-existing low-grade dysplasia: a case report. Am J Gastroenterol. 2007;102:1545-1546.
185. Palascak-Juif V, Bouvier AM, Cosnes J, et al. Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo. Inflamm Bowel Dis. 2005;11:828-832.
186. Elriz K, Carrat F, Bouvier AM, et al. Small bowel adenocarcinoma during Crohn's disease: a prospective observational cohort study. Gastroenterology. 2011;140(suppl 1):430.
187. Eaton JE, Silveira MG, Pardi DS, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol. 2011;106:1638-1645.
188. Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 2011;54:1842-1852.
189. Baars JE, Kuipers EJ, van Haastert M, et al. Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey. J Gastroenterol. 2012;47:1308-1322.
190. Shaukat A, Virnig DJ, Salfiti NI, et al. Is inflammatory bowel disease an important risk factor among older persons with colorectal cancer in the United States? A population-based case-control study. Dig Dis Sci. 2011; 56:2378-2383.
191. Kariv R, Remzi FH, Lian L, et al. Preoperative colorectal neoplasia increases risk for pouch neoplasia in patients with restorative proctocolectomy. Gastroenterology. 2010;139:806-812.
192. Sinclair JA, Wasan SK, Farraye FA. Health maintenance in the inflammatory bowel disease patient. Gastroenterol Clin North Am. 2012;41: 325-337.
193. Mamula P, Markowitz JE, Piccoli DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:851-856.
194. Gelinck LB, van der Bijl AE, Beyer WE, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response. Ann Rheum Dis. 2008;67:713-716.
195. Agarwal N, Ollington K, Kaneshiro M, et al. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine. 2012;30:1413-1424.
196. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59:1-62.
197. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2009. Ann Intern Med. 2009; 150:40-44.
198. Esteve M, Saro C, González-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004;53:1363-1365.
199. Montiel PM, Solis JA, Chirinos JA, et al. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int. 2008;28:718-720.
200. Cardell K, Akerlind B, Sällberg M, et al. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis. 2008;198:299-304.
201. Dotan I, Vigodman S, Malter L, et al. Azathioprine/6-mercaptopurine therapy has no significant effect on cellular or humoral immune responses in patients with inflammatory bowel disease. Gastroenterology. 2007;132:A-51.
202. Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-4):1-40.
203. Singh A, Englund K. Q: Who should receive the shingles vaccine? Cleve Clin J Med. 2009;76:45-48.
204. Kotton CN. Nailing down the shingles in IBD. Inflamm Bowel Dis. 2007; 13:1178-1179.
205. Jyrkkä J, Enlund H, Lavikainen P, et al. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf. 2011;20:514-522.
206. Cahir C, Fahey T, Teeling M, et al. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol. 2010;69:543-552.
207. Akazawa M, Imai H, Igarashi A, et al. Potentially inappropriate medication use in elderly Japanese patients. Am J Geriatr Pharmacother. 2010;8:156-160.
208. Siddiqi N, House AO, Holmes JD. Occurrence and outcome of delirium in medical in-patients: a systematic literature review. Age Ageing. 2006; 35:350-364.
209. Alagiakrishnan K, Wiens CA. An approach to drug induced delirium in the elderly. Postgrad Med J. 2004;80:388-393.
210. Kojima T, Akishita M, Nakamura T, et al. Association of polypharmacy with fall risk among geriatric outpatients. Geriatr Gerontol Int. 2011;11: 438-444.
211. Fletcher PC, Berg K, Dalby DM, et al. Risk factors for falling among community-based seniors. J Patient Saf. 2009;5:61-66.
212. Boyle N, Naganathan V, Cumming RG. Medication and falls: risk and optimization. Clin Geriatr Med. 2010;26:583-605.
213. Sergi G, De Rui M, Sarti S, et al. Polypharmacy in the elderly. Can comprehensive geriatric assessment reduce inappropriate medication use? Drugs Aging. 2011;28:509-518.
214. Harrison MJ, Kim CA, Silverberg M, et al. Does age bias the aggressive treatment of elderly patients with rheumatoid arthritis? J Rheumatol. 2005;32:1243-1248.
215. Fleischmann RM, Baumgartner SW, Tindall EA, et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol. 2003;30:691-696.
216. Fleischmann RM, Baumgartner SW, Weisman M, et al. Long-term safety of etancercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. 2006;65:379-384.
217. Bathon JM, Fleischmann RM, Van der Heijde D, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol. 2006;33:234-243.
218. Genevay S, Finckh A, Ciurea A, et al. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population based cohort study. Arthritis Rheum. 2007; 57:679-685.
219. Salliot C, Gossec L, Ruyssen-Witrand A, et al. The risk of serious infections is higher in daily practice than in clinical trials for rheumatic patients receiving TNF blockers: a systematic retrospective study of 770 patients. Arthritis Rheum. 2005;52(suppl):S340. Abstract 858.
220. Chevillotte-Maillard E, Ornetti P, Mistrih R, et al. Survival and safety of treatment with infliximab in the elderly population. Rheumatology. 2005; 44:695-696.
221. Davas EM, Alexiou I, Boulbou M, et al. Co-morbidities increase the risk of serious infections in patients with rheumatoid arthritis treated with TNFalpha inhibitors. J Infect. 2008;57:418-420.
222. Köller MD, Aletaha D, Funovits J, et al. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology. 2009;48:1575-1580.
223. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:1754-1764.
224. Remicade®(infliximab) current prescribing information. 2009.
225. Massara A, Govoni M, Trotta F. High incidence of serious adverse events among elderly rheumatoid patients receiving monoclonal antibodies anti-TNF alpha. Ann Rheum Dis. 2007;66(suppl II): Abstract THU0184. EULAR 2007; Barcelona, Spain, June 13-16, 2007.
226. Cottone M, Kohn A, Daperno M, et al. Age is a risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30-35.